Graphene Manufacturing Group Ltd

ACN 614 164 877

Condensed consolidated interim financial statements for the three months ended 30 September 2022 and 2021

Graphene Manufacturing Group Ltd Condensed Consolidated Interim Financial Statements For the three months ended 30 September 2022 and 2021

Contents

	Page
Corporate information	3
Condensed consolidated interim statement of profit or loss and other comprehensive income	4
Condensed consolidated interim statement of financial position	5
Condensed consolidated interim statement of changes in equity	6
Condensed consolidated interim statement of cash flows	7
Notes to the condensed consolidated interim financial statements	8

Corporate information

The condensed consolidated interim financial statements of Graphene Manufacturing Group Ltd ("**GMG**" or the "**Company**") for the three months ended 30 September 2022 were authorised for issue in accordance with a resolution of the directors on 23 November 2022. The Company is a limited liability company incorporated and domiciled in Australia, and whose shares are publicly traded on the TSX Venture Exchange (the "**TSXV**").

The reviewed consolidated interim financial statements are presented in Australian dollars (\$ or A\$), except for certain references to Canadian dollars (C\$) where specifically stated.

Directors

Guy Outen
Craig Nicol
Robbert De Weijer (resigned 15 July 2022)
Robert Shewchuk
William Ollerhead
Emma FitzGerald (appointed 1 July 2022)
Frederick Kotzee (appointed 22 August 2022)

Registered office

Graphene Manufacturing Group Ltd 5/848 Boundary Road Richlands QLD 4077 Australia

Principal place of business

Graphene Manufacturing Group Ltd 5/848 Boundary Road Richlands QLD 4077 Australia

Share registrar and transfer agent

Computershare Investor Services Inc. 510 Burrard Street Vancouver BC V6C 3B9 Canada

Auditors

BDO Audit Pty Ltd Level 10, 12 Creek Street Brisbane QLD 4000 Australia

Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income

		Three mont	
	Note	2022 A\$	2021 A\$
Revenue	6	85,890	13,020
Other income	7(a)	142,639	4,088
Employee benefit expenses	7(b)	(1,566,796)	(896,087)
Professional and consulting fees	` ,	(433,111)	(410,321)
Depreciation and amortisation expense	10,11	(217,465)	(36,255)
Travel expenses	,	`(78,115)	(911)
Raw materials and production inputs		(25,203)	(8,398)
Occupancy and utilities expenses		(83,832)	(37,443)
Factory costs		(99,442)	(36,021)
Share based payments expense		(278,550)	(44,898)
Other expenses	7(b)	(283,449)	(103,343)
Finance costs	7(c)	(28,289)	(5,395)
Gain / (loss) on change in fair value of warrants	13(a)	(692,910)	2,402,649
Profit / (loss) before income tax	, ,	(3,558,633)	840,685
Income tax expense	8	-	-
Profit / (loss) for the period		(3,558,633)	840,685
24 (20)			
Other comprehensive income (OCI)			007
Foreign currency translation differences			367
Net OCI that may be reclassified to profit or loss in			267
subsequent periods		-	367
OCI for the period, net of tax		<u>-</u>	367
Total comprehensive profit / (loss) for the period		(3,558,633)	841,052
Earnings / (loss) per share attributable to the ordinary equity holders of the Group:			
Basic and diluted (cents)	9	(4.51)	1.18
Weighted average number of ordinary shares outstanding	^	, ,	74 505 000
(Basic and diluted)	9	78,915,842	71,535,899

The above condensed consolidated interim statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

Condensed Consolidated Interim Statement of Financial Position

	Note	30 September 2022 A\$	30 June 2022 A\$
ASSETS			
Current assets			
Cash and cash equivalents		8,406,295	12,258,018
Trade and other receivables		302,773	142,876
Inventories		334,434	350,388
Research and development grants receivables		1,554,070	1,411,926
Other current assets		368,932	317,884
		10,966,504	14,481,092
Non-current assets	4.0		0.400.474
Property, plant and equipment	10 11	2,936,360	2,162,174
Intangible assets	11	1,984,352	32,663
		4,920,712	2,194,837
Total assets		15,887,216	16,675,929
LIABILITIES Current liabilities			
Trade and other payables		1,291,211	804,078
Lease liabilities	12	248,650	136,622
Financial liabilities	13	4,743,733	4,410,364
Employee benefit liabilities		250,286	207,064
Provisions		20,000	20,000
		6,553,880	5,578,128
Non-current liabilities			
Lease liabilities	12	1,239,313	897,627
Provisions		200,000	100,000
		1,439,313	997,627
Total liabilities		7,993,193	6,575,755
Net assets		7,894,023	10,100,174
EQUITY			
Share capital	14	27,149,701	26,435,310
Share capital warrant premium	14	6,331,212	5,971,671
Reserves	15	2,081,443	1,802,893
Accumulated losses		(27,668,333)	(24,109,700)
Total equity		7,894,023	10,100,174

The above condensed consolidated interim statement of financial position should be read in conjunction with the accompanying notes.

Condensed Consolidated Interim Statement of Changes in Equity

	Note	Share capital A\$	Reserves A\$	Accumulated losses A\$	Total equity A\$
Balance at 1 July 2021	-	13,851,483	563,476	(12,380,536)	2,034,423
Profit for the period		-	-	840,685	840,685
Other comprehensive income / (loss)		-	(40,735)	41,102	367
Total comprehensive profit / (loss) for the period	· ·	-	(40,735)	881,787	841,052
Transactions with owners of the Company					
Shares issued	14	9,694,304	-	-	9,694,304
Transaction costs on issued shares	14	(1,321,790)	-	-	(1,321,790)
Share options and warrants exercised	14	127,749	-	-	127,749
Share based payments	_	-	237,465	-	237,465
		8,500,263	237,465	-	8,737,728
Balance at 30 September 2021		22,351,746	760,206	(11,498,749)	11,613,203
Balance at 1 July 2022	=	32,406,981	1,802,893	(24,109,700)	10,100,174
Loss for the period		-	-	(3,558,633)	(3,558,633)
Other comprehensive income	15	-	-	-	_
Total comprehensive loss for the period		-	-	(3,558,633)	(3,558,633)
Transactions with owners of the Company					
Shares issued	14	500,000	-	-	500,000
Share options and warrants exercised	14	214,391	-	-	214,391
Share capital warrant premium	14	359,541	-	-	359,541
Share based payments	15(a)	-	278,550	-	278,550
		1,073,932	278,550	-	1,352,482
Balance at 30 September 2022		33,480,913	2,081,443	(27,668,333)	7,894,023

The above condensed consolidated interim statement of changes in equity should be read in conjunction with the accompanying notes.

Condensed Consolidated Interim Statement of Cash Flows

		Three months ended	
		30 Septe	ember
	Note	2022 A\$	2021 A\$
		·	<u> </u>
Operating activities			
Receipts from customers and government subsidies		107,930	28,464
Payments to suppliers and employees	<u>-</u>	(2,765,942)	(1,518,769)
		(2,658,012)	(1,490,305)
Interest received		495	695
Interest paid		(18,970)	-
Net cash used in operating activities		(2,676,487)	(1,489,610)
Investing activities			
Acquisition of property, plant and equipment		(315,040)	(111,944)
Acquisition of intangibles	14	(1,007,102)	-
Net cash used in investing activities		(1,322,142)	(111,944)
Financing activities			
Proceeds from issue of shares		-	9,822,053
Proceeds from issue of share warrants		-	3,634,424
Proceeds from exercise of share options	14	22,781	-
Proceeds from exercise of share warrants	14	191,610	-
Share issue transaction costs		-	(1,101,712)
Payment of lease liabilities		(67,485)	-
Net cash from financing activities		146,906	12,354,765
Net increase / (decrease) in cash and cash equivalents		(3,851,723)	10,753,211
Cash and cash equivalents at 1 July		12,258,018	3,359,087
Cash and cash equivalents at 30 September		8,406,295	14,112,298

The above condensed consolidated interim statement of cash flows should be read in conjunction with the accompanying notes.

1. Reporting entity

Graphene Manufacturing Group Ltd ("GMG" or the "Company") and its subsidiaries (collectively, the "Group") is a for-profit company primarily involved in the development of technology and manufacture of graphene powder and energy saving and energy storage solutions enabled by graphene. The Company is a limited liability company incorporated and domiciled in Australia, and whose shares are publicly traded on the TSX Venture Exchange (the "TSXV").

2. Basis of preparation

These condensed consolidated interim financial statements ("interim financial statements") as at and for the three months ended 30 September 2022 and 2021 have been prepared in accordance with IAS 34 Interim Financial Reporting, and should be read in conjunction with the Group's last annual consolidated financial statements as at and for the year ended 30 June 2022 ("last annual financial statements"). They do not include all of the information required for a complete set of financial statements prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"). However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual financial statements.

These interim financial statements were authorised for issue by the Company's board of directors on 23 November 2022.

(a) Going concern

The condensed consolidated interim financial statements have been prepared on a going concern basis which contemplates the continuity of normal business activities and the realisation of assets and discharge of liabilities in the normal course of operations.

For the three month period ended 30 September 2022, the Group incurred a loss of \$3,558,633 after income tax and net cash outflows from operating activities of \$2,676,487. At 30 September 2022, the Group had net current assets of \$4,412,624 (30 June 2022: \$8,902,964).

The ability of the Group to continue as a going concern is principally dependent upon current cash funding held and the ability to raise additional capital or secure other forms of financing, as and when necessary to meet the levels of expenditure required for the Group. This is required to continue its ongoing development and commercialisation of energy saving and energy storage solutions and to meet the consolidated Group's working capital requirements.

These conditions give rise to material uncertainty which may cast significant doubt over the Group's ability to continue as a going concern.

Whilst acknowledging these uncertainties, the Directors have concluded that the going concern basis of preparation of the financial statements is appropriate considering the following circumstances:

- As at 30 September 2022, the Group had cash on hand of \$8,406,295, which together with the Bought Deal Unit Offering as disclosed in note 18(a), is sufficient to meet the ongoing corporate costs and expected project expenditure for twelve (12) months;
- As at the date of this report there are 4,498,559 options and 2,205,875 warrants on issue with exercise prices ranging from AUD\$0.36 to AUD\$2.91. If exercised these could raise up to \$8,791,315 in additional capital;
- The Group continues to closely monitor expenditure, and the Board is confident that it will be able to manage its cash resources appropriately;
- The Group continues to engage with potential energy saving products customers with the aim to increase sales; and
- To the extent required, the Group has capacity under the TSXV Listing Rules to raise further funds through the issue or placement of securities.

2. Basis of preparation (continued)

(a) Going concern (continued)

Should the Group be unable to continue as a going concern, it may be required to realise its assets and extinguish its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial report. This financial report does not include any adjustments related to the recoverability and classification of recorded asset amounts or classification of liabilities and appropriate disclosures that may be necessary should the Group be unable to continue as a going concern.

3. Use of judgements and estimates

In preparing these interim financial statements, management has made judgements and estimates that affect the application of the Group's accounting policies and the reported amounts of assets, liabilities, revenue and expense. Actual results may differ from these estimates.

Significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

4. Change in accounting policies

The accounting policies adopted in the preparation of the interim financial statements are consistent with those followed in the preparation of the Group's last annual financial statements for the year ended 30 June 2022. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

5. Operating segments

The Company's senior management represent the Chief Operating Decision Makers ("CODM"). The CODM analyses the company information as a whole and as such, have determined that the Company has only one operating segment. Revenue from the operating segment is not significant enough to be separately measured, and all sales come from energy saving and energy storage solutions mainly in Australia. Assets are all based in Australia.

Sale of goods		2022 A\$	2021 A\$
Case Disaggregation of revenue from contracts with customers The Group derives revenue from the transfer of goods as follows:	6. Revenue from contracts with customers		
Timing of revenue recognition	Sale of goods	85,890	13,020
Timing of revenue recognition At a point in time 85,890 13,020 Over time - - 7. Income and expenses - - (a) Other income - <	(a) Disaggregation of revenue from contracts with customers		
At a point in time Over time 85,890 13,020 Over time 85,890 13,020 7. Income and expenses Income and expenses (a) Other income Interest income Research and development tax incentive Interest income 142,144 -	The Group derives revenue from the transfer of goods as follows:		
7. Income and expenses (a) Other income 495 695 695 695 0142,639 4,088 0142,639 4,088 4,088 4,088 142,639 4,088 142,639 4,088 1	At a point in time	85,890 -	13,020
Research and development tax incentive		85,890	13,020
Research and development tax incentive Interest income 142,144	7. Income and expenses		
Interest income 495 695 Other income - 3,393 142,639 4,088 (b) Notable expenses Employee benefit expenses include the following notable item: Superannuation 122,692 72,800 Other expenses include the following notable items: Filling fee expenses 72,145 2,549 Licensing and registration expenses 54,215 5,734 Insurance 53,695 31,682 Testing and quality control 40,364 15,746 Information technology expenses 27,172 16,665 Research and development expenses 10,644 - Share registry and other listing expenses 6,077 11,049 (c) Finance costs 8,455 4,364 Interest expense – lease liabilities 18,574 - Finance and other interest charges 1,260 1,031	(a) Other income		
(b) Notable expenses Employee benefit expenses include the following notable item: Superannuation Other expenses include the following notable items: Filing fee expenses Licensing and registration expenses Insurance Testing and quality control Information technology expenses Research and development expenses Information technology expenses Research and development expenses Private of the following notable items: 10,644 15,746 10,644 10,644 11,049 11,049 11,049 11,049	Interest income		
Employee benefit expenses include the following notable item: 122,692 72,800 Other expenses include the following notable items: 72,145 2,549 Licensing fee expenses 72,145 5,734 Licensing and registration expenses 54,215 5,734 Insurance 53,695 31,682 Testing and quality control 40,364 15,746 Information technology expenses 27,172 16,665 Research and development expenses 10,644 - Share registry and other listing expenses 6,077 11,049 (c) Finance costs Foreign exchange losses 8,455 4,364 Interest expense – lease liabilities 18,574 - Finance and other interest charges 1,031		142,639	4,088
Superannuation 122,692 72,800 Other expenses include the following notable items: Filing fee expenses 72,145 2,549 Licensing and registration expenses 54,215 5,734 Insurance 53,695 31,682 Testing and quality control 40,364 15,746 Information technology expenses 27,172 16,665 Research and development expenses 10,644 - Share registry and other listing expenses 6,077 11,049 (c) Finance costs Foreign exchange losses 8,455 4,364 Interest expense – lease liabilities 18,574 - Finance and other interest charges 1,260 1,031	(b) Notable expenses		
Other expenses include the following notable items: Filing fee expenses 72,145 2,549 Licensing and registration expenses 54,215 5,734 Insurance 53,695 31,682 Testing and quality control 40,364 15,746 Information technology expenses 27,172 16,665 Research and development expenses 10,644 - Share registry and other listing expenses 6,077 11,049 (c) Finance costs 8,455 4,364 Interest expense – lease liabilities 18,574 - Finance and other interest charges 1,260 1,031	Employee benefit expenses include the following notable item:		
Filing fee expenses 72,145 2,549 Licensing and registration expenses 54,215 5,734 Insurance 53,695 31,682 Testing and quality control 40,364 15,746 Information technology expenses 27,172 16,665 Research and development expenses 10,644 - Share registry and other listing expenses 6,077 11,049 (c) Finance costs 8,455 4,364 Interest expense – lease liabilities 18,574 - Finance and other interest charges 1,260 1,031	Superannuation	122,692	72,800
Licensing and registration expenses 54,215 5,734 Insurance 53,695 31,682 Testing and quality control 40,364 15,746 Information technology expenses 27,172 16,665 Research and development expenses 10,644 - Share registry and other listing expenses 6,077 11,049 (c) Finance costs 8,455 4,364 Interest expense – lease liabilities 18,574 - Finance and other interest charges 1,260 1,031	Other expenses include the following notable items:		
(c) Finance costsForeign exchange losses8,4554,364Interest expense – lease liabilities18,574-Finance and other interest charges1,2601,031	Licensing and registration expenses Insurance Testing and quality control Information technology expenses Research and development expenses	54,215 53,695 40,364 27,172 10,644	5,734 31,682 15,746 16,665
Interest expense – lease liabilities 18,574 - Finance and other interest charges 1,031	(c) Finance costs		
Finance and other interest charges 1,260 1,031	•		4,364 -
		1,260 28,289	1,031 5,395

8. Income tax expense

Deferred tax assets are recognised only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses. The unused tax losses incurred by the Company are not recognised as there is uncertainty on the expected timing in which the Company is likely to generate taxable income in the foreseeable future. Subject to satisfying certain tests under the relevant legislation they can be carried forward indefinitely. As a consequence, there is no income tax expense.

9. Earnings per share

Basic earnings or loss per share ("**EPS**") calculations have been based on the following profit/(loss) attributable to ordinary equity holders divided by the weighted average number of ordinary shares outstanding.

Diluted EPS calculations have been based on the following loss attributable to ordinary equity holders and weighted average number of ordinary shares outstanding after adjustment for the effects of all dilutive potential ordinary shares.

Due to the net loss recognised for the years, and the ongoing non-cash impact on profit and loss due to the change in the fair value of warrants, to ensure consistency and relevance of reporting, all outstanding stock options, warrants and broker warrants were excluded from the calculation of diluted EPS due to their anti-dilutive effect.

	Three months ended 30 September	
	2022 A\$	2021 A\$
Basic and diluted EPS (cents)	(4.51)	1.18
Profit / (loss) attributable to ordinary equity holders of the Company for basic earnings – continuing operations	(3,558,633)	840,685
Profit / (loss) attributable to ordinary equity holders of the Company adjusted for the effect of dilution	(3,558,633)	840,685
_	2022 Number	2021 Number
(a) Weighted average number of ordinary shares ("WANOS")		
WANOS used in basic and diluted EPS	78,915,842	71,535,899

Items excluded from the diluted weighted average number of ordinary shares calculation as their effect would have been anti-dilutive:

	Number as at 30 September		
	2022	2021	
Stock options	4,498,559	5,639,079	
Warrants	2,672,600	4,543,500	
Broker warrants	84,287	279,924	
Restricted and performance share units	982,479	-	
	8,237,925	10,462,503	

10. Property, plant and equipment

	Right-of-use (i) Property		Right-of-use (i)		
	Leased buildings A\$	Plant and equipment ⁽ⁱⁱ⁾ A\$	Leasehold improvements A\$	Capital work in progress A\$	Total A\$
Cost					
At 30 June 2022	1,208,374	1,722,603	412,438	253,375	3,596,790
Additions	475,654	11,280	-	315,040	801,974
Transfers	-	90,319	88,364	(178,683)	-
At 30 September 2022	1,684,028	1,824,202	500,802	389,732	4,398,764
Accumulated depreciation					
At 30 June 2022	134,264	1,285,276	15,076	-	1,434,616
Remeasurement	(134,264)	-	-	-	(134,264)
Depreciation	84,202	57,805	20,045	-	162,052
At 30 September 2022	84,202	1,343,081	35,121	-	1,462,404
Net book value					
At 30 June 2022	1,074,110	437,327	397,362	253,375	2,162,174
At 30 September 2022	1,599,826	481,121	465,681	389,732	2,936,360

⁽i) Right-of-use ("ROU") asset recognised in respect of the Company's head office and warehouse leased premises in Brisbane, Australia, as disclosed in note 12, with the corresponding lease accounting policy as described in note 31 of the last annual financial statements for the year ended 30 June 2022.

11. Intangible assets

3	Patents, trademarks and other rights A\$	Computer software A\$	Total A\$
Cost			
At 30 June 2022	37,609	16,266	53,875
Additions	2,007,102	-	2,007,102
At 30 September 2022	2,044,711	16,266	2,060,977
Accumulated amortisation			
At 30 June 2022	16,459	4,753	21,212
Amortisation	54,593	820	55,413
At 30 September 2022	71,052	5,573	76,625
Net book value			
At 30 June 2022	21,150	11,513	32,663
At 30 September 2022	1,973,659	10,693	1,984,352

⁽ii) Plant and equipment cost includes \$24,246 of leased office equipment recognised as a ROU asset as the lease term exceeds 12 months.

	30 September 2022 A\$	30 June 2022 A\$
12. Lease liabilities		
Maturity analysis of contractual undiscounted cash flows:		
Within one year	348,980	193,758
Between one and five years	1,418,384	931,627
More than five years	-	84,729
	1,767,364	1,210,114
Lease liabilities included in the condensed consolidated interim statement of financial position:		
Current	248,650	136,622
Non-current	1,239,313	897,627
	1,487,963	1,034,249

Right-of-use asset and lease liability

(a)

Warrant liability

In July 2022, the Company replaced its prior three-year lease agreement for the existing head office leased premises in Brisbane, Australia, with a five-year lease agreement including an additional warehouse in the same location. A right-of-use asset of \$1,684,028 has been recognised, as disclosed in note 10, assessed on its five-year lease term, which is subject to annual review. The corresponding lease liability of \$1,531,451 has been recognised together with a provision for make good of \$200,000.

	30 September 2022 A\$	30 June 2022 A\$
13. Financial liabilities	-	
Warrant liability:		
Traded warrants	3,368,334	2,919,815
Non-traded warrants	1,375,399	1,490,549
	4,743,733	4,410,364

The Company has issued certain share purchase warrants which have a fixed exercise price in Canadian dollars. As the functional currency of the Company is the Australian dollar, these warrants are considered a derivative as a variable amount of cash in the Company's functional currency will be received on exercise. The share purchase warrants were not issued for goods or services rendered. Accordingly, these warrants are classified and accounted for as a derivative financial liability at fair value through profit or loss. The fair value of the warrants is determined using the quoted market trading data for the Company's traded warrants, and

The changes in the carrying amounts of the Company's outstanding warrant liability during the three month period ended 30 September 2022 and 2021 were as follows:

	2022 A\$	2021 A\$
At 1 July	4,410,364	2,188,625
Issued during the period	-	3,634,424
Exercised	(359,541)	-
Expired	-	-
Fair value adjustment	692,910	(2,402,649)
At 30 September	4,743,733	3,420,400

Further details of the warrants issued are disclosed in note 14(b).

the Black-Scholes option pricing model for non-traded warrants.

13. Financial liabilities (continued)

(a) Warrant liability (continued)

Non-traded warrants

The fair value of non-traded warrants and stock options classified as derivative financial liabilities was calculated with the following weighted average assumptions:

	30 September 2022	30 June 2022
Share price	C\$2.95	C\$2.73
Exercise price	C\$1.00 - C\$2.60	C\$1.00 - C\$2.60
Expected volatility	79.6%	79.6%
Expected life (years)	0.04 - 1.93	0.29 – 2.18
Risk-free interest rate	3.43% - 3.57%	2.73% - 3.16%

Traded warrants

The Marketed Offering Warrants issued on 2 September 2021 commenced trading on the TSXV on 9 September 2021. On initial recognition and prior to active market trading data being available for use, the Marketed Offering Warrants were valued using the Black Scholes option pricing model based on the inputs below:

	On initial recognition
Share price	C\$2.73
Exercise price	C\$2.60
Expected volatility	61%
Expected life (years)	2.99
Risk-free interest rate	0.20%

Once trading of the warrants commenced, the quoted market trading data on the TSXV was available for use as a Level 1 input to determine the fair value. At 30 September 2022 the fair value of traded warrants was based on the market price of C\$1.50 per warrant at the end of the reporting period.

14. Share capital

•		Thr	ee months end	led 30 Septemi	ber
		2022	2022	2021	2021
	Note	Number	A\$	Number	A\$
Ordinary shares		79,103,586	33,480,913	75,786,408	22,351,746
(a) Movement in ordinary shares					
At 1 July		78,764,797	32,406,981	69,545,092	13,851,483
Shares issued – Marketed Offering		-	-	5,635,000	8,903,056
Shares issued - Private Placement		-	-	425,000	791,248
Shares issued – OzKem Transaction	(i)	125,207	500,000	-	-
Share options exercised	(ii)	37,348	22,781	100,000	61,000
Warrants exercised	(iii)	176,234	191,610	81,316	66,749
Transaction costs for issued shares		-	-	-	(1,321,790)
		79,103,586	33,121,372	75,786,408	22,351,746
Share capital warrant premium		-	359,541	-	-
At 30 September		79,103,586	33,480,913	75,786,408	22,351,746

(i) Share issue - OzKem Transaction

On 15 August 2022, GMG and OzKem Pty Ltd ("OzKem") signed a binding agreement for GMG to acquire the manufacturing intellectual property and brand rights of OzKem's THERMAL-XR® coating products for a cash consideration of \$1 million, in addition to \$1 million in ordinary shares of GMG (the "OzKem Transaction"). GMG paid OzKem an initial A\$1 million cash and issued 125,207 ordinary shares of GMG ("Shares") to OzKem upon the receipt of certain deliverables and equipment from OzKem on 8 September 2022 and 22 September 2022 respectively. GMG will issue an additional 125,206 Shares (the "Additional Shares") to OzKem, conditional on a successful commercial batch blend of the THERMAL XR® product being completed by GMG.

- (ii) Share options exercised
 Shares issued upon the exercise of options allocated under the Stock Option Plan detailed in note 16(a).
- (iii) Warrants exercised
 Shares issued upon the exercise of warrants detailed in note 14(b).

14. Share capital (continued)

(b) Warrants

Warrants, including broker warrants, outstanding at the end of the period have the following expiry dates and exercise prices:

			30 September	30 June
Issue date	Expiry date	Exercise price	2022	2022
0.4 Marrala 0004	04.0	O#0.05		40.050
24 March 2021	24 September 2022	C\$0.65	-	40,050
13 April 2021	13 October 2022	C\$1.00	491,000	621,377
2 September 2021	2 September 2024	C\$2.60	1,994,100	1,996,100
2 September 2021	2 September 2024	C\$2.05	16,180	18,718
2 September 2021	2 September 2024	C\$2.60	187,500	187,500
2 September 2021	2 September 2024	C\$2.14	5,760	5,760
9 November 2021	2 September 2024	C\$2.60	62,347	62,347
Total			2,756,887	2,931,852

The number and weighted average exercise price ("WAEP") of warrants, which are all exercisable, were as follows:

	Three months ended 30 September			
	2022 2022		2021	2021
	WAEP_	Number	WAEP	Number
Outstanding at 1 July	\$2.51	2,931,852	\$0.53	1,699,930
Granted	\$2.85	1,269	\$2.76	3,204,810
Exercised	\$1.09	(176,234)	\$0.82	(81,316)
Outstanding at 30 September	\$2.60	2,756,887	\$2.14	4,823,424

There were no warrants forfeited or expired since the end of the last reporting year ended 30 June 2022 and during the three month period ended 30 September 2022.

15. Reserves		30 September 2022 A\$	30 June 2022 A\$
Share-based payment reserve		1,647,453	1,368,903
Warrants reserve		433,990	433,990
		2,081,443	1,802,893
(a) Movements in reserves			
	Share-Based Payment A\$	Warrants A\$	Total A\$
At 30 June 2022	1,368,903	433,990	1,802,893
Stock option plan expense	2,641	-	2,641
RSUs expense	217,333	-	217,333
			50 570
PSUs expense	58,576	-	58,576

16. Share-based payments

(a) Stock option plan and Share Incentive Plan

The establishment of the stock option plan and the Share Incentive Plan were approved by resolutions of shareholders dated 19 September 2018 and 25 November 2021 respectively. The plans are designed to provide eligible participants with an opportunity to share in the ownership of the Company in order to:

- promote the long-term success of the Company;
- provide a strategic, value based reward for eligible persons who make a key contribution to that success;
- align eligible persons' interests with the interests of the Company's shareholders; and
- promote the retention of eligible participants.

Eligible participants under each plan are any director, executive officer, employee or consultant of the Company as decided upon by the board to be eligible under the terms of the respective plan.

Options, RSUs and PSUs may be granted on commercial terms approved by the board, which may include but are not limited to vesting conditions based on length of service and performance of the eligible participant, or the Company's share price. Participation in each plan is at the board's discretion.

Options, RSUs and PSUs are granted under the respective plan for no consideration and carry no dividend or voting rights. Upon exercise or settlement, each option, RSU and PSU is convertible into one ordinary share.

(b) Restricted share units ("RSUs") and performance share units ("PSUs")

Equity settled

Under the terms of the share incentive plan ("**Share Incentive Plan**") the Board of Directors may, from time to time, grant to directors, executive officers, employees and consultants, RSUs and PSUs in such numbers and on such terms as determined by the board. RSUs and PSUs granted under the Share Incentive Plan, are exercisable into ordinary shares for no additional consideration, after the vesting conditions specified within the terms of each participants' agreement are met.

The fair value of RSUs and PSUs was determined based on the Company's share price on the date of grant.

The RSUs vest in one to three tranches with vesting conditions based on time and share price performance over its respective one to three-year period. The PSUs vest in three tranches with vesting conditions based on time and performance targets over a three-year period.

Share-based payments expense related to the RSUs and PSUs are recorded over the respective one to three-year vesting period and the amount is adjusted at each reporting period to reflect the number of RSUs and PSUs expected to vest.

(c) Reconciliation of outstanding share options

Share options, granted as share based payments, outstanding at the end of the period have the following expiry dates and exercise prices:

Grant date	Expiry date	Exercise price (i)	30 September 2022 ⁽ⁱ⁾	30 June 2022 ⁽ⁱ⁾
6 November 2018	4 November 2025	\$0.36	2,222,654	2,222,654
18 February 2019	16 February 2026	\$0.50 \$0.61	220,000	220,000
•	•	·	,	·
15 March 2019	13 March 2026	\$0.61	200,000	200,000
20 March 2019	18 March 2026	\$0.61	29,326	29,326
12 May 2019	10 May 2026	\$0.61	-	37,348
2 December 2019	30 November 2026	\$0.42	440,000	440,000
6 April 2020	5 April 2027	\$0.61	29,326	29,326
21 April 2020	20 April 2027	\$0.61	285,000	285,000
23 December 2020	22 December 2027	\$0.82	791,780	868,648
12 March 2021	10 March 2028	\$0.94	29,348	44,000
15 April 2021	12 March 2024	C\$0.4963	151,125	151,125
16 April 2021	15 April 2024	C\$1.00	100,000	100,000
Total			4,498,559	4,627,427

The number and weighted average exercise price ("WAEP") of share options representing share based payments, were as follows:

	Three months ended 30 September				
	2022	2022 2022		2021	
	WAEP (i)	Number	WAEP (i)	Number	
Outstanding at 1 July	\$0.52	4,627,427	\$0.53	5,739,079	
Exercised	\$0.61	(37,348)	\$0.61	(100,000)	
Forfeited	\$0.84	(91,520)	-	-	
Outstanding at 30 September	\$0.52	4,498,559	\$0.53	5,639,079	
Exercisable at 30 September	\$0.48	3,835,127	\$0.46	3,029,987	

⁽i) Adjusted for the impact of the Share Split Transaction per note 22(a)(ii) of the last annual financial statements for the year ended 30 June 2022.

There were no options granted or expired since the end of the last reporting year ended 30 June 2022 and during the three month period ended 30 September 2022.

(d) Reconciliation of outstanding broker warrants

Broker warrants, issued as share based payments, outstanding at the end of the period have the following expiry dates and exercise prices:

			30 September	30 June
Issue date	Expiry date	Exercise price	2022	2022
24 March 2021	24 September 2022	C\$0.65	-	40,050
2 September 2021	2 September 2024	C\$2.05	16,180	18,718
2 September 2021	2 September 2024	C\$2.14	5,760	5,760
9 November 2021	2 September 2024	C\$2.60	62,347	62,347
Total			84,287	126,875

The number and weighted average exercise price ("WAEP") of broker warrants, issued as share based payments which are all exercisable, were as follows:

	Three months ended 30 September			
	2022 WAEP	2022 Number	2021 WAEP	2021 Number
Outstanding at 1 July	\$2.12	126,875	\$0.70	161,430
Issued	\$2.85	1,269	\$2.39	249,975
Exercised	\$0.88	(43,857)	\$1.86	(215,664)
Outstanding at 30 September	\$2.77	84,287	\$1.59	195,741

There were no broker warrants forfeited or expired since the end of the last reporting year ended 30 June 2022 and during the three month period ended 30 September 2022.

Further details in respect of broker warrants held at reporting date are provided in note 14(b).

(e) Reconciliation of outstanding RSUs and PSUs

RSUs and PSUs, granted as share based payments, outstanding at the end of the period, have the following expiry dates:

			30 September	30 June
Grant date	Expiry date	Plan Type	2022	2022
20 October 2021	20 October 2026	RSU	181,960	181,960
20 October 2021	20 October 2026	PSU	77,359	77,359
5 December 2021	5 December 2026	RSU	15,662	15,662
14 September 2022	14 September 2027	RSU	453,847	-
20 September 2022	20 September 2027	RSU	253,651	-
Total			982,479	274,981

(e) Reconciliation of outstanding RSUs and PSUs (continued)

The number and weighted average share price ("WASP") of RSUs and PSUs were as follows:

	Three months ended 30 September		
	2022	2022	
	WASP (i)	Number	
RSUs			
Outstanding at 1 July	\$6.24	197,622	
Granted	\$4.20	707,498	
Outstanding at 30 September	\$4.65	905,120	
Exercisable at 30 September	-	-	
PSUs			
Outstanding at 1 July	\$6.28	77,359	
Outstanding at 30 September	\$6.28	77,359	
Exercisable at 30 September	-		

(i) Further details of fair value measurement are included in note 16(g).

Since the end of the last reporting year ended 30 June 2022 and during the three month period ended 30 September 2022 there were no:

- RSUs exercised, forfeited or expired; and
- PSUs granted, exercised, forfeited or expired.

There were no RSUs or PSUs in the prior comparative three month period ended 30 September 2021.

(f) Fair value measurement of options and warrants granted

The assessed fair value of options granted during the three months ended 30 September 2022 was nil (year ended 30 June 2022: nil). The assessed fair value of warrants granted during the three months ended 30 September 2022 was nil (year ended 30 June 2022: \$408,367).

The fair value at grant date is determined using a Black-Scholes Model that takes into account the exercise price, the term of the option, the market price of a share at grant date and expected price volatility of the underlying share, the risk-free interest rate for the term of the option and the volatilities of certain peer group companies.

(f) Fair value measurement of options and warrants granted (continued)

The fair value of options granted and warrants issued during the three months ended 30 September 2022, and the year ended 30 June 2022, was calculated using the exercise price, grant date and expiry date as per above with the following weighted average assumptions:

On initial recognition	Options		Warrants	
	30 September 2022	30 June 2022	30 September 2022	30 June 2022
Share price at grant date	-	-	-	\$3.19
Expected volatility	-	-	-	61%
Risk-free interest rate	-	-	-	0.18%

(i) Weighted average share price at grant date includes options granted prior to listing on the TSXV, adjusted for the impact of the Share Split Transaction per note 22(a)(ii) of the last annual financial statements for the year ended 30 June 2022.

Options are granted for no consideration and vested options are exercisable until the expiry date which is between two to seven years after grant date. The expected price volatility is based on the historic volatility of certain peer group companies, and since the listing of the Company's traded warrants, the implied volatility of the Company's shares calculated by reference to those warrants.

(g) Fair values of RSUs and PSUs granted

The assessed fair value of RSUs and PSUs granted during the three months ended 30 September 2022 was \$2,970,273 (year ended 30 June 2022: \$1,692,837) and is based on the Company's share price on the date of grant.

The RSUs vest in one to three tranches with vesting conditions based on time and share price performance over its respective one to three-year period. The PSUs vest in three tranches with vesting conditions based on time and performance targets over a three-year period.

Share-based payments expense related to the RSUs and PSUs are recorded over the respective one to threeyear vesting period and the amount is adjusted at each reporting period to reflect the number of RSUs and PSUs expected to vest.

The fair value of RSUs and PSUs granted during the three months ended 30 September 2022, and the year ended 30 June 2022, was calculated at the grant date based on the following weighted average assumptions:

	RSUs		PSUs	
On initial recognition	30 September 2022	30 June 2022	30 September 2022	30 June 2022
Share price at grant date	\$4.20 ⁽ⁱ⁾	\$6.24 (ii)	-	\$6.28 ⁽ⁱⁱ⁾

- (i) The fair value of RSUs granted during the three month period ended 30 September 2022, was based on the share price on 25 August 2022 and 2 September 2022 in accordance with employment agreement terms and the Share Incentive Plan.
- (ii) The fair value of RSUs and PSUs granted on 20 October 2021, was based on the share price at the date on which shareholder approval was obtained for the Company's Share Incentive Plan, at the Annual General Meeting held on 25 November 2021 (Eastern Standard Time).

17. Commitments and contingencies

The Company's commitments and contingencies are consistent with those reported in the last annual financial statements as at 30 June 2022.

18. Subsequent events

With the exception of the matter noted below, no other matters or circumstances have occurred since the end of the reporting period, which significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in subsequent reporting periods.

(a) Bought Deal Unit Offering

On November 8, 2022, GMG entered into an agreement pursuant to which Eight Capital as lead underwriter and sole bookrunner, together with a syndicate of underwriters (collectively, the "**Underwriters**"), will purchase 1,819,000 units of the Company (the "**Units**"), on a "bought deal" basis pursuant to the filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of C\$2.75 (the "**Issue Price**") for gross proceeds of C\$5,002,250 (the "**Offering**").

Each Unit shall be comprised of one common share in the capital of the Company (a "**Share**") and one common share purchase warrant (a "**Warrant**"). Each Warrant shall entitle the holder thereof to purchase one Share at an exercise price of C\$3.35 for a period of 48 months following the closing date of the Offering.

The Company has agreed to grant the Underwriters an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, and/or the components thereof, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering.